行情

JAGX

JAGX

Jaguar Health
NASDAQ

实时行情|Nasdaq Last Sale

1.670
-0.030
-1.76%
盘后: 1.650 -0.02 -1.20% 19:49 06/22 EDT
开盘
1.690
昨收
1.700
最高
1.690
最低
1.600
成交量
490.57万
成交额
--
52周最高
4.470
52周最低
0.1850
市值
2.29亿
市盈率(TTM)
-1.8636
分时
5日
1月
3月
1年
5年
12 只医疗保健股在周三的盘后交易时段内移动
Gainers
Benzinga · 6天前
Jaguar Health & Dragon SPAC 宣布向 Dragon SPAC 提供 1080 万美元的初始资金
Jaguar Health, Inc. ("Jaguar") and Milan, Italy-based Dragon SPAC S.p.A. ("Dragon SPAC") today announced the initial funding of the private financing of Dragon SPAC, which has named as its target Napo
Benzinga · 06/01 12:33
周三盘中交易的12种医疗保健股
 
Benzinga · 05/26 16:54
Jaguar Health提供有关Canalevia的最新消息;说,如果有条件批准,Canalevia将在第四季度上市
Canalevia would be first and only FDA-approved plant-based medicine for dogs that suffer from diarrhea during chemotherapy Canalevia will be available by fourth quarter 2021, if conditionally approved SAN
Benzinga · 05/18 12:40
为什么Jaguar Health的股票今天下跌
Jaguar Health (NASDAQ:JAGX) shares are trading lower after the company reported worse-than-expected Q1 EPS results.
Benzinga · 05/17 19:15
回顾:捷豹健康Q1收入
  Shares of Jaguar Health (NASDAQ:JAGX) decreased 1.6% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 83.93% year over year to ($0.09), which missed the estimate of ($0.02).
Benzinga · 05/17 12:52
Jaguar Health Q1 EPS $(0.10)未达到$(0.02)估计,销售额为124万美元,较去年同期的$ 869.00K
Jaguar Health (NASDAQ:JAGX) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.02) by 400 percent. This is a 82.14 percent increase over losses of $(0.56) per share from the
Benzinga · 05/17 12:22
预计2021年5月17日的收入
  Companies Reporting Before The Bell • Hycroft Mining Holding (NASDAQ:HYMC) is estimated to report earnings for its first quarter.
Benzinga · 05/17 08:10
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解JAGX最新的财务预测,通过JAGX每股收益,每股净资产,每股现金流等数据分析Jaguar Health近期的经营情况,然后做出明智的投资选择。
分析师评级

1位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测JAGX价格均价为4.500,最高价位4.500,最低价为4.500。
EPS
机构持股
总机构数: 48
机构持股: 971.07万
持股比例: 7.07%
总股本: 1.37亿
类型机构数股数
增持
9
394.35万
建仓
31
362.26万
减持
1
1.14万
平仓
6
22.22万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+0.14%
制药与医学研究
-0.24%
高管信息
Chairman/Independent Director
James Bochnowski
President/Chief Executive Officer/Director
Lisa Conte
Chief Financial Officer/Chief Accounting Officer
Carol Lizak
Executive Vice President/Secretary
Steven King
Senior Vice President
Melissa Yeager
Chief Compliance Officer/General Counsel
Jonathan Wolin
Independent Director
Gregory Divis
Independent Director
John Micek
Independent Director
Jiahao Qiu
Independent Director
Jonathan Siegel
暂无数据
JAGX 简况
Jaguar Health Inc是一家天然产品制药公司。该公司专注于在全球范围开发和商业化用于人类处方药和动物的新型可持续来源的胃肠产品。该公司通过其子公司Napo Pharmaceuticals Inc专注于从热带雨林地区的传统植物开发和商业化人类胃肠道药物,并面向全球市场。它的Mytesi是一种抗腹泻药,用于抗逆转录病毒疗法的人类免疫缺陷病毒HIV/获得性免疫缺陷综合症(AIDS)成年患者的非感染性腹泻症状缓解。其他产品包括Canalevia、Equilevia、Neorom Calf和Neonorm Foal。

微牛提供Jaguar Health Inc(NASDAQ-JAGX)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的JAGX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易JAGX股票基本功能。